845616-82-2

Basic information

• Product Name: (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid
• Synonyms: (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid;(S)-5-(methylsulfonyl)-2-((1,1,1-trifluoropropan-2-yl)oxy)benzoic acid
• CAS NO: 845616-82-2
• Molecular Formula: C₁₁H₁₁F₃O₅S
• Molecular Weight: 312.2622496
• Mol File: 845616-82-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid(845616-82-2)
• EPA Substance Registry System: (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid(845616-82-2)

Safety Data

• Hazardous Substances Data: 845616-82-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid is used as a potential drug candidate for the treatment of various medical conditions. Its unique structural features allow it to bind to specific biological targets, making it a valuable compound in the development of new therapeutics.
Used in Laboratory Experiments and Chemical Synthesis:
In addition to its pharmaceutical applications, (S)-2-(1-Methyl-2,2,2-trifluoroethoxy)-5-Methylsulfonylbenzoic acid is also utilized as a reagent in laboratory settings. Its complex structure and chiral properties make it a useful tool for a range of chemical synthesis and experimental procedures.

Upstream product

• 845617-20-1 5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-benzoic acid methyl ester 
• 247569-56-8 2-fluoro-5-(methylsulfonyl)benzoic acid 
• 374-01-6 (S)-1,1,1-trifluoro-2-propanol 
• 37098-75-2 2-fluoro-5-chlorosulfonylbenzoic acid 
• 445-29-4 o-fluoro-benzoic acid 
• 865663-98-5 2-fluoro-5-methanesulfonylbenzoic acid methyl ester 

Downstream Products

• 845614-11-1 Bitopertin 
• 1258507-84-4 C₁₉H₁₇ClF₃NO₄S 
• 1258507-85-5 C₁₉H₁₈F₃NO₄S 
• 905269-98-9 C₂₀H₂₀F₃NO₅S 

Relevant articles and documents

Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties

We report here the identification and optimization of a novel series of potent GlyT1 inhibitors. A ligand design campaign that utilized known GlyT1 inhibitors as starting points led to the identification of a novel series of pyrrolo[3,4-c]pyrazoles amides

Bitopertin synthetic method and intermediate

The present invention discloses a new synthesis method and intermediates of Bitopertin. According to the Bitopertin synthesis method, 5-methylsulfonyl-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]benzoic acid is adopted as a raw material, and continuous multi-step operations such as chlorination, acylation, deprotection, condensation and re-crystallization are subjected to performed to obtain the Bitopertin, wherein the intermediates in each step do not require further purification, and the total yield can achieve more than or equal to 80%.

Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5- trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2, 2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.

Preparation of dihydropyrrol derivatives as intermediates

The invention is concerned with a new scalable process for the preparation of compounds of formula I comprising a new process for the preparation of the key intermediate, a dihydropyrrole derivative formula II or a salt thereof.

SYNTHESIS OF GLYT-1 INHIBITORS

The present invention relates to a process for preparation of a compound of formula I wherein Het, R1, R2, R3, and n are as defined herein and pharmaceutically acceptable acid addition salts thereof, which comprises reacting a compound of formula 21 with a compound of formula 8 to obtain a compound of formula 11 and coupling the compound of formula 11 in the presence of a coupling reagent or the corresponding acid halogenide with a compound of formula 15 to obtain a compound of formula I.

Substituted phenyl methanone derivatives

The present invention relates to compounds of formula I wherein R1, R2, R3, n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors

Heterocyclic-substituted phenyl methanones

The present invention relates to compounds of formula I wherein R1, R2, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.

Substituted phenyl methanones

The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R″ and R1, R2,R3, R4, R5, and R6 are as defined

[4-(HETEROARYL) PIPERAZIN-1-YL]-(2,5-SUBSTITUTED -PHENYL)METHANONE DERIVATIVES AS GLYCINE TRANSPORTER 1 (GLYT-1) INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS

The present invention relates to compounds of the general formula (I) wherein R1 is-OR1’,-SR1’ or is a heterocycloalkyl group; R1’ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n